1. Evidence-based public policy making for medicines across countries: findings and implications for the future
- Author
-
Dan Kibuule, Ileana Mardare, Tomasz Bochenek, Amanj Kurdi, Stephen Campbell, Johanna C Meyer, Vanda Marković-Peković, Joseph O Fadare, Aubrey Chichonyi Kalungia, Alice Pisana, Hye Young Kwon, Isabella Piassi Godói, Brian Godman, Zikria Saleem, Carolina Zampirolli Dias, Antony P. Martin, Sylvia Opanga, Iris Hoxha, and Eleonora Allocati
- Subjects
Evidence-based practice ,Coronavirus disease 2019 (COVID-19) ,Public economics ,business.industry ,030503 health policy & services ,Health Policy ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Public policy ,Biosimilar ,Orphan diseases ,RS ,03 medical and health sciences ,0302 clinical medicine ,Health care ,Drugs, Generic ,Humans ,Medicine ,Narrative review ,030212 general & internal medicine ,Health Expenditures ,Policy Making ,0305 other medical science ,business ,Biosimilar Pharmaceuticals - Abstract
Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.
- Published
- 2021
- Full Text
- View/download PDF